logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Regeneron Stock Is Soaring

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals ( REGN ) stock outperformed last week gaining over $27. The stock’s soaring was not the outcome of the market’s outperformance, for several consecutive days, but because the firm has announced great news...

Read More

February 10, 2020

0

CRISPR gene editing firms clear investors' confusion

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific articles that meant to caution about possible problems or by patents that were given to some Universities and denied it to others and vice...

Read More

September 12, 2018

0

Cassava Sciences Has Good News from Alzheimer's Disease Trial. See Also: Theravance Biopharma

Cassava Sciences From   NEWSWIRE  we learned that Cassava Sciences ( SAVA ) , a clinical-stage biotechnology company focusing on Alzheimer’s disease, announced that The Journal of Prevention of Alzheimer’s Disease ( JPAD ), a peer-reviewed journal for the research community, has published...

Read More

February 12, 2020

0

News from NKTR, BMY and MRK. See Also: Biotechs' Bizarre Performances in Early Trading Hours Today

News from Nektar Nektar Therapeutics ( NKTR ) announced that new data from patients with metastatic triple-negative breast cancer, who were enrolled in the PIVOT-02 study, will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference being held from September...

Read More

September 24, 2019

0

The Medicines Company: Improving Atherosclerotic Cardiovascular Diseases (ASCVD)

The Medicines Company ORION-10 Study for ASCVD The Medicines Company ( MDCO ) announced positive topline results from the ORION-10 Phase 3 clinical trial in patients with atherosclerotic cardiovascular disease ( ASCVD ). The ORION-10 trial conducted with the product...

Read More

September 26, 2019

0

AcelRx Pharmaceuticals: A small currently highlighted firm

Today, we see are observing an increased interest in AcelRx Pharmaceuticals (ACRX) . The increased investors’ activity happened following the announcement that an Advisory Committee meeting will soon review the firm’s New Drug Application (NDA) for Dsuvia ( Sufentanil) developed...

Read More

September 14, 2018

0

Enanta Product EPD-305 Has Promising Results for the Treatment NASH

Enanta Positive Results of EPD-305 for NASH Enanta ( ENTA ) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305 for the treatment of non-alcoholic steatohepatitis ( NASH ).  ...

Read More

September 28, 2019

0

CRISPR Therapeutics' new collaboration targeting Diabetes

CRISPR  Gene Editing Beyond Bringing Cures  to disease-causing genes, CRISPR gene editing technology can change the way diseases are being treated and treat diseases that have yet to find a treatment. CRISPR gene editing can play a key role in...

Read More

September 19, 2018

0

Seattle Genetics' Product Tucatinib Beats Agressive Colorectal Cancer. The Stock Price Soars

Seattle Genetics Stock Rally Seattle Genetics ( SGEN ) stock has rallied today. It gained around $10; trading at over $85, nearing the Prohost 2019 $90 target. The reason for investors’ great enthusiasm is Seattle Genetics announcement of a presentation at the...

Read More

September 30, 2019

0

About Portola's appointment of a new president. Read Also: Why CRISPR lost $2.90 today

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed a new president, Mr. Scott Garland, who was Relypsa’s president and previously chief commercial officer and responsible for the integration and growth of the...

Read More

September 20, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 82
  • 83
  • 84
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy